- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 390
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 247
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lead Poisoning, Environmental Exposure
- Interventions
- Intensive Public Health Campaign, Standard Information Dissemination
- Behavioral
- Lead sponsor
- International Health Strategies LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lead Poisoning, Vitamin D Deficiency
- Interventions
- d-penicillamine, placebo
- Device · Drug
- Lead sponsor
- FDA Office of Orphan Products Development
- Federal
- Eligibility
- 6 Months to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Shellfish Poisoning, Paralytic
- Interventions
- Middle school education program
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Hoonah, Alaska • Juneau, Alaska • Sitka, Alaska
- Conditions
- Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Scorpion Sting
- Interventions
- Anascorp
- Biological
- Lead sponsor
- Instituto Bioclon S.A. de C.V.
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 3
- States / cities
- San Carlos, Arizona • Tucson, Arizona
- Conditions
- Ricin Poisoning
- Interventions
- 50-μg booster dose RVEc
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neurotoxicity
- Interventions
- NeurOptics® NPi®-300 Pupillometer
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carbon Monoxide Exposure
- Interventions
- Not listed
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Advanced Cancers
- Interventions
- Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lead Poisoning
- Interventions
- Education on behaviors to reduce lead exposure
- Behavioral
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Wyandotte, Oklahoma
- Conditions
- Fluid Retention, Fluid Loss, Sodium Retention, Cognitive Change, Heat Exposure, Hyperhydration, Electrolyte and Fluid Balance Conditions
- Interventions
- PR Lotion - AMP Human Performance, Placebo Lotion
- Other
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Storrs, Connecticut
- Conditions
- Lymphoma
- Interventions
- Simvastatin, Dexamethasone
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication, Malignant Ovarian Mixed Epithelial Tumor, Neurotoxicity Syndrome, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
- Interventions
- Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Camden, New Jersey + 4 more
- Conditions
- Carbon Monoxide Intoxication
- Interventions
- Observational data collection.
- Device
- Lead sponsor
- Nonin Medical, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Brain Cancer, Brain Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 20 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anxiety, Fatigue, Nausea and Vomiting, Neurotoxicity Syndrome, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Assessment of Therapy Complications, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 144
- States / cities
- Aurora, Colorado • Hartford, Connecticut • New Britain, Connecticut + 105 more
- Conditions
- Seizure, Alcohol Related
- Interventions
- levetiracetam
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Neuropsychiatric Sequelae of Carbon Monoxide Poisoning
- Interventions
- HBOT
- Drug
- Lead sponsor
- Paul G. Harch, M.D.
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Marrero, Louisiana
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
- Interventions
- ONM-501, Cemiplimab
- Drug
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Interventions
- Envarsus, IR Tacrolimus
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Sepsis, AKI, Neurotoxicity
- Interventions
- anti-pseudomonal cephalosporin, anti-pseudomonal penicillin
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hypersensitivity, Immediate
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 19 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland